EDESA BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.37 USD | -1.13% |
|
-0.23% | -4.38% |
| Mar. 05 | Top Premarket Gainers | MT |
| Feb. 09 | Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 77.54 | 97.83 | 14.25 | 13.33 | 14.05 | - | - |
| Enterprise Value (EV) 1 | 77.54 | 97.83 | 14.25 | 13.33 | 14.05 | 14.05 | 14.05 |
| P/E ratio | -10.9 x | -6.71 x | -0.88 x | -1.51 x | -1.88 x | -2.62 x | -3.08 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 236 x | - | - | - | - | - | - |
| EV / Revenue | 236 x | - | - | - | - | - | - |
| EV / EBITDA | - | -4,151,759 x | - | - | - | - | - |
| EV / FCF | - | -7,155,688 x | - | - | - | - | - |
| FCF Yield | - | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,373 | 1,894 | 2,209 | 3,013 | 3,216 | - | - |
| Reference price 2 | 56.49 | 51.66 | 6.449 | 4.424 | 4.370 | 4.370 | 4.370 |
| Announcement Date | 12/7/20 | 12/28/21 | 12/16/22 | 12/15/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Settembre | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.3288 | - | - | - | - | - | - |
| EBITDA | - | -23.56 | - | - | - | - | - |
| EBIT 1 | -6.401 | -23.68 | -18.37 | -9.223 | -9.135 | -20.3 | -27.1 |
| Operating Margin | -1,946.73% | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.363 | -13.34 | -17.55 | -8.374 | -8.625 | -10.4 | -14.2 |
| Net income 1 | -6.364 | -13.34 | -17.55 | -8.374 | -8.625 | -10.4 | -14.2 |
| Net margin | -1,935.59% | - | - | - | - | - | - |
| EPS 2 | -5.180 | -7.700 | -7.350 | -2.930 | -2.323 | -1.665 | -1.420 |
| Free Cash Flow | - | -13.67 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 12/7/20 | 12/28/21 | 12/16/22 | 12/15/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.485 | -5.162 | -4.575 | -5.798 | -2.836 | -2.378 | -2.411 | -2.064 | -2.37 | -1.857 | -2.25 | -2.317 | -2.683 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.686 | -4.379 | -4.569 | -5.787 | -2.814 | -2.335 | -2.334 | -1.985 | -1.72 | -1.678 | -2.17 | -2.19 | -2.573 |
| Net income 1 | -3.686 | -4.379 | -4.569 | -5.787 | -2.814 | -2.335 | -2.334 | -1.985 | -1.72 | -1.678 | -2.17 | -2.19 | -2.573 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.890 | -2.310 | -2.310 | -2.590 | -0.0700 | -0.9100 | -0.8400 | -0.7000 | -0.4800 | -0.5400 | -0.6933 | -0.5233 | -0.6200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/28/21 | 2/14/22 | 5/13/22 | 8/12/22 | 12/16/22 | 2/10/23 | 5/11/23 | 8/9/23 | 12/15/23 | 2/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -13.7 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 0.01 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 12/7/20 | 12/28/21 | 12/16/22 | 12/15/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.37
USD
Average target price
24
USD
Spread / Average Target
+449.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.38% | 14.05M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.46% | 22.18B | |
| -16.67% | 21.2B | |
| -8.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- EDSA Stock
- Financials Edesa Biotech, Inc.
